EyePoint (EYPT)

EyePoint’s lead programme is DURAVYU, also known as EYP-1901, a sustained-release investigational therapy designed to deliver a tyrosine kinase inhibitor directly inside the eye over an extended period. The product candidate uses the company’s Durasert technology platform, which is intended to provide controlled local drug release. If successful, the approach could offer physicians another way to manage chronic retinal disease while potentially lowering the frequency of injections compared with standard anti-VEGF treatment schedules.

The company’s pipeline also includes EYP-2301, an earlier-stage programme using an enhanced Durasert platform to deliver razuprotafib. Razuprotafib is a Tie2 pathway activator that targets vascular stability, a key biological mechanism in several retinal diseases. This programme reflects EyePoint’s broader focus on pairing known or emerging therapeutic mechanisms with long-acting ocular delivery.

As a biotech company, EyePoint’s value is closely linked to clinical trial results, regulatory progress, intellectual property, manufacturing execution, and the commercial potential of its pipeline. It operates in a specialised but significant ophthalmology market where durable therapies are highly sought after because many retinal conditions require long-term, repeated treatment to preserve vision.